Geron Corp. Stock
Price
Target price
€3.46
€3.46
-1.470%
-0.052
-1.470%
€4.63
13.05.24 / Tradegate
WKN: 902213 / Symbol: GERN / Name: Geron / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Geron Corp. Stock
A loss of -1.470% shows a downward development for Geron Corp..
Geron Corp. is currently one of the favorites of our community with 12 Buy predictions and no Sell predictions.
As a result the target price of 4 € shows a slightly positive potential of 15.54% compared to the current price of 3.46 € for Geron Corp..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Geron Corp. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Geron Corp. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
C******** o* t** e**********
Cons
?
B****
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Geron Corp. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Geron Corp. | -1.470% | 0.058% | 1.021% | 21.388% | 75.915% | 215.301% | 133.919% |
Ardelyx Inc. | 2.910% | -12.617% | 12.153% | 87.355% | 28.685% | 32.821% | - |
Evolus Inc | -1.690% | -4.918% | 4.505% | 26.087% | 28.177% | 71.852% | - |
Salarius Pharmaceuticals Inc. | -2.300% | -0.469% | 3.922% | -61.802% | -23.604% | -98.261% | -99.992% |
Comments
Geron Co. (NASDAQ: GERN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.
Show more
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) is now covered by analysts at TD Cowen. They set a "buy" rating and a $10.00 price target on the stock.
Show more
Ratings data for GERN provided by MarketBeat
Geron Co. (NASDAQ: GERN) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $5.00 price target on the stock.
Show more
Ratings data for GERN provided by MarketBeat
News
Geron (GERN) Q1 2024 Earnings Call Transcript
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
Geron Inc. (NASDAQ: GERN) is a clinical-stage biotech in the medical sector focused on developing cell therapies to treat certain types of blood cancers and myeloid hematologic malignancies. Their